Interleukin-2 receptor-directed therapies: antibody- or cytokine-based targeting molecules.

With the exception of certain hematologic malignancies, the high affinity interleukin-2 (IL-2) receptor is only transiently expressed during the brief antigen-triggere d proliferative burst oflymphocytes. Hence, we wondered whether administration of anti-IL-2 receptor (lL-2R) monoclonal anti­ body (mAb) or chimeric IL-2 toxins would provide a utilitarian way to achieve immunosuppressio n

[1]  J. Reuben,et al.  DAB486IL-2 fusion toxin in refractory rheumatoid arthritis. , 1993, Arthritis and rheumatism.

[2]  N. Tanaka,et al.  Cloning of the gamma chain of the human IL-2 receptor. , 1992, Science.

[3]  Katherine A. Kantardjieff,et al.  The crystal structure of diphtheria toxin , 1992, Nature.

[4]  J. Reuben,et al.  Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. , 1992, Blood.

[5]  T. Strom,et al.  Selective elimination of HIV-1-infected cells with an interleukin-2 receptor-specific cytotoxin , 1991, Science.

[6]  N. F. Landolfi.  A chimeric IL-2/Ig molecule possesses the functional activity of both proteins. , 1991, Journal of immunology.

[7]  M Levitt,et al.  A humanized antibody that binds to the interleukin 2 receptor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[8]  O. Petersen,et al.  Immunotoxins--entry into cells and mechanisms of action. , 1989, Immunology today.

[9]  D. Regier,et al.  Design, synthesis and expression of a human interleukin-2 gene incorporating the codon usage bias found in highly expressed Escherichia coli genes. , 1988, Nucleic acids research.

[10]  Lutz Riechmann,et al.  Reshaping human antibodies for therapy , 1988, Nature.

[11]  I. Pastan,et al.  Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[12]  W. Bishai,et al.  Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. , 1987, Protein engineering.

[13]  T. Waldmann,et al.  Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[14]  W. Bishai,et al.  Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related alpha-melanocyte-stimulating hormone fusion protein. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[15]  T. Strom,et al.  Rapid stereospecific stimulation of lymphocytic metabolism by interleukin 2. , 1985, Journal of Immunology.

[16]  S L Morrison,et al.  Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Cantrell,et al.  The interleukin-2 T-cell system: a new cell growth model. , 1984, Science.